Drug · CHEMBL730

NITROGLYCERIN

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. NITROGLYCERIN. Drugs and targets, record CHEMBL730. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL730

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: NITROGLYCERIN; ChEMBL
ChEMBL ID: CHEMBL730; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Coro-nitro, Deponit 10, Deponit 5, Glytrin, Gonitro, Lenitral 7.5, Minitran, Minitran 10, Minitran 15, Minitran 5, Natirose, Nitriderm tts, Nitro iv, Nitro-bid, Nitro-dur, Nitro-mack ret, Nitrocine, Nitrocontin continus, Nitrol, Nitrolingual, Nitrolingual pumpspray, Nitromin, Nitromist, Nitronal, Nitrostat, Percutol, Rectiv, Rectogesic, Suscard buccal, Sustac, Transderm-nitro, Transiderm-nitro 10, Transiderm-nitro 5, Tridil, Trintek 10, Trintek 15, Trintek 5; ChEMBL
Other names: C01DA02, Chlormethine oxide hydrochloride, Diluted nitroglycerin, Glonoinum, Glyceryl trinitrate, Glyceryl trinitrate solution, Imx-150, Mechlorethamine oxide hcl, Mitomen, Mustron, Nitora, Nitroglycerin tablets, Nitromin hydrochloride, Trinitrin, Trinitrine; ChEMBL
DrugBank: DB00727; DrugBank
InChIKey: SNIOPGDIGTZGOP-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 10 of its 54 diseases, from ATC, DailyMed and TTD; Open Targets

Targets3

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
GUCY1A1	Soluble guanylate cyclase	Soluble guanylate cyclase activator	ACTIVATOR	https://conductscience.org/library/genes/2982
GUCY1A2	Soluble guanylate cyclase	Soluble guanylate cyclase activator	ACTIVATOR	https://conductscience.org/library/genes/2977
GUCY1B1	Soluble guanylate cyclase	Soluble guanylate cyclase activator	ACTIVATOR	https://conductscience.org/library/genes/2983

Source ChEMBL

Diseases54

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
coronary artery disorder	Approval	DailyMed	53	5	https://conductscience.org/library/drugs?q=MONDO_0005010
Anal fissure	Phase 3	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=HP_0012390
non-small cell lung carcinoma	Phase 2	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MONDO_0005233
hypertensive disorder	Approval	DailyMed	8	4	https://conductscience.org/library/drugs?q=MONDO_0005044
angina pectoris	Approval	DailyMed and TTD	56	3	https://conductscience.org/library/drugs?q=EFO_0003913
Breech presentation	Phase 2/3	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=HP_0001623
acute kidney injury	Unknown	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0002492
migraine disorder	Unknown	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0005277
erectile dysfunction	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0005362
preeclampsia	Unknown	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0005081

1 to 10 of 54Source Open Targets

See all 54 diseases

Trials176

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 7 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT03158532	Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin	Phase 3	2,040	2024-12-09	nitroglycerin	Its name	ClinicalTrials.gov
NCT02343276	Randomized Clinical Trial Comparing Transradial Catheterization With or Without Spasmolytic Drugs	Phase 3	328	2019-05-31	nitroglycerin	Its name	ClinicalTrials.gov
NCT01387672	Nitrates and Bone Turnover; Nitrates and Bone Turnover Bisphosphonate Sub-Study	Phase 3	265	2015-05-08	nitroglycerin	Its name	ClinicalTrials.gov
NCT00522041	A Study to Determine the Effect of Nitroglycerin Ointment 0.4% (Cellegesic) on the Pain Associated With Chronic Anal Fissures	Phase 3	248	2016-11-03	nitroglycerin	Its name	ClinicalTrials.gov
NCT02495467	Clinical Trial of Topically-applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction (ED)	Phase 2	232	2020-01-29	glyceryl trinitrate	Its name	ClinicalTrials.gov
NCT02961946	Effects of Sublingual and Transdermal Administration of Nitroglycerin for Coronary CT Angiography on Image Quality	Phase 4	198	2019-09-17	nitroglycerin	Its name	ClinicalTrials.gov
NCT02714205	Flushing Reduction Associated With Nitrates	Phase 2	141	2023-05-18	nitroglycerin	Its name	ClinicalTrials.gov
NCT01999517	Contrast Nephropathy and Nitrates	Phase 4	122	2019-10-29	nitroglycerin	Its name	ClinicalTrials.gov
NCT02832115	Topical Nitroglycerine Treatment for Radial Artery Spasm Prevention	Phase 4	100	2020-10-27	nitroglycerin	Its name	ClinicalTrials.gov
NCT01996436	The Intra-arterial Vasospasm Trial	Phase 4	92	2025-05-11	nitroglycerin	Its name	ClinicalTrials.gov

1 to 10 of 176

See all 176 trials

Comparisons in its trials34

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
MED2005 vs MED Placebo: deaths from any cause	0 of 229	0 of 227	456	NCT02495467	Trial comparisons
MED2005 vs MED Placebo: serious adverse events	0 of 229	0 of 227	456	NCT02495467	Trial comparisons
MED2005 vs MED Placebo: Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 1	94 of 216	56 of 216	432	NCT02495467	Trial comparisons
MED2005 vs MED Placebo: Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 2	85 of 216	54 of 216	432	NCT02495467	Trial comparisons
Intervention vs Placebo: serious adverse events	0 of 164	0 of 164	328	NCT02343276	Trial comparisons
Cellegesic (Nitroglycerin 0.4%) vs Placebo: serious adverse events	2 of 123	1 of 124	247	NCT00522041	Trial comparisons
Transdermal Nitroglycerin vs Placebo: deaths from any cause	0 of 70	0 of 71	141	NCT02714205	Trial comparisons
Transdermal Nitroglycerin vs Placebo: serious adverse events	0 of 70	0 of 71	141	NCT02714205	Trial comparisons
Transdermal Nitroglycerin vs Placebo: Number of Participants With Treatment Related Severe Adverse Events Defined by Common Terminology Criteria for Adverse Events (CTCAE) Severity Grade 3 or Higher.	0 of 66	0 of 71	137	NCT02714205	Trial comparisons
Vascana vs Vehicle Cream: Raynaud's Symptom Severity (Percentage of Responders)	37 of 65	29 of 65	130	NCT02688270	Trial comparisons

1 to 10 of 34

See all 34 comparisons in its trials

Papers from its trials156

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39878173	RESULT	1	PubMed
39840843	RESULT	1	PubMed
39028048	RESULT	1	PubMed
38490779	RESULT	1	PubMed
37658717	RESULT	1	PubMed
37546514	RESULT	1	PubMed
37303880	RESULT	1	PubMed
36872649	RESULT	1	PubMed
36357803	RESULT	1	PubMed
35249707	RESULT	1	PubMed

1 to 10 of 156

See all 156 papers from its trials

Tests in its trials2

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Stroop Color-Word Test	1	0	ConductCognition
Verbal Learning	1	0	ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL730

GET https://conductscience.org/api/drugs/v1/CHEMBL730/diseases?page=2

API reference For AI assistants